Table 2 Clinical characteristics of CD20-negative diffuse large B-cell lymphoma and CD20-positive diffuse large B-cell lymphoma patients

Age(years)

Median (range)

51.5(9-83)

53(11-83)

51(9-71)

0.955

≤60

56(66.7%)

14(66.7%)

42(66.7)

1

Sex

Male

64(76.2%)

16(76.2%)

48(76.2%)

1

Female

20(23.8%)

5(23.8%)

15(23.8%)

PS score

0-1

75(89.3%)

18(85.7%)

57(90.5%)

0.839

≥2

9(10.7%)

3(14.3%)

6(9.5%)

Stage

I-II

49(58.3%)

12(57.1%)

37(58.7%)

0.898

III-IV

35(41.7%)

9(42.9%)

26(41.3%)

LDH

Normal

50(59.5%)

14(66.7%)

36(57.1%)

0.441

Elevated

34(40.5%)

7(33.3%)

27(42.9%)

Extranodal sites

0-1

73(86.9%)

16(76.2%)

57(90.5%)

0.191

≥2

11(13.1%)

5(23.8%)

6(9.5%)

IPI

0-1

44(52.4%)

11(52.4%)

33(52.4%)

1

2-3

40(47.6%)

10(47.6%)

30(47.6%)

Bulky disease

Yes

20(23.8%)

8(38.1%)

12(19%)

0.076

No

64(76.2%)

13(61.9%)

51(81%)

BM involvement

Yes

2(2.4%)

2(9.5%)

0(0)

0.06

No

82(97.6%)

19(90.5%)

63(100%)

B symptom

Present

23(27.4%)

8(38.1%)

15(23.8%)

0.204

Absent

61(72.6%)

13(61.9%)

48(76.2%)

First-line chemotherapy

CHOP or CHOP-like

79(94%)

20(95.2%)

59(93.7%)

1

Other regimens

5(6%)

1(4.8%)

4(6.3%)

Radiotherapy

Yes

28(33.3%)

5(23.8%)

23(36.5%)

0.285

No

56(66.7%)

16(76.2%)

40(63.5%)

Surgery

Yes

11(13.1%)

5(23.8%)

6(9.5%)

0.191

No

73(86.9%)

16(76.2%)

57(90.5%)

Autologous SCT

Yes

4(4.8%)

1(4.8%)

3(4.8%)

1

No

80(95.2%)

20(95.2%)

60(95.2%)

Follow-up (months)

Median (range)

41.5(2-121)

13(3-117)

47(2-121)